A Pilot Study of Autologous Bone Marrow Transplantation Followed by Recombinant Interleukin-2 in Malignant Lymphomas

References

• Philip T., Armitage J. O., Spitzer G., Chauvin F., Jagannath S., Cahn J. C. P., Goldstone A., Gorin N., Flesh M., Laporte J. M. D., Pico J., Bosly A., Anderson C., Schots R., Biron P., Cabanillas F., Dicke K. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non Hodgkin's lymphoma. N. Engl. J. Med 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Jagannath S., Armitage J. O., Dicke K. A., Tucker S. L., Velasquez W. S., Smith K., Vaughan W. P., Kessinger A., Honwitz L. J., Hagemeister F. B., McLaughlin P., Cabanillas F., Spitzer G. Pronostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol 1989; 7: 179–185
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Jagannath S., Spitzer G., Bierner P., Kersinger A., Kumar P., Cabanillas F., Zander A., Vellekoop L., Dicke K. A. High-dose chemotherapy and autologous bone marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. Europ. J. Cancer Clin. Oncol 1988; 22: 871–877
   Google Scholar
• Mills W., Chopra R., McMillan A., Linch D. C., Goldstone A. H. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non Hodgkin's lymphoma. J. Clin. Oncol 1995; 13: 588–595
   PubMed Web of Science ®Google Scholar
• Surbone A., Armitage J. O., Gale R. P. Autotransplantation in lymphoma: better therapy or healthier patients?. Ann. Intern. Med 1991; 114: 1059–1060, (editorial).
   PubMed Web of Science ®Google Scholar
• Jones R. J., Ambinder R. F., Piantadosi S., Santos G. W. Evidence of a graft versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V., Uberti J., Karanes C., Abella E., Lum L. G., Momin F., Cummings G., Sensenbrenner L. L. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non Hodgkin's lymphoma. Blood 1994; 84: 1050–1055
   PubMed Web of Science ®Google Scholar
• Weiden P. L., Flournoy N., Thomas E. D., Prentice R., Fefer A., Buckner C., Storb R. Antileukemic effect of graft versus host disease in human recipients of allogeneic marrow grafts. N. Engl. J. Med 1979; 300: 1068–1070
   PubMed Web of Science ®Google Scholar
• Morgan D. A., Ruscetti F. W., Gallo R. W. Selective in vitro growth of lymphocytes from normal human bone marrow. Science 1976; 193: 1007–1011
   PubMed Web of Science ®Google Scholar
• Rosenberg A., Lotze M. T., Muul L. M., Chang A., Avis F., Leitman S., Linehan M., Robertson L., Lee R., Rubin J., Seipp C., Simpson C., White D. A progress report on the treatment of 157 patients with advanced cancer using activated killer cells and interleukine-2 or high dose interleukine-2 alone. N. Engl. J. Med 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Blaise D., Viens P., Brandely M., Olive D., Lopez M., Sainty D., Marit G., Stoppa A. M., Reiffers J., Gratecos N., Bertau-Perez P., Mannoni P., Mawas C., Hercend T., Sebahoun G., Carcassonne Y. High-dose recombinant interleukine-2 and acute myeloid leukemias in relapse. Blood 1991; 78: 2182–2187
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C., Maraninchi D., Pico J. L., Milpied N., Coiffier B., Divine M., Tiberghien P., Bosly A., Tilly H., Boulat O., Brandely M. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994; 83: 2081–2085
   PubMed Web of Science ®Google Scholar
• Allison M. A., Jones S. E., Mc Guffy P. Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia and selected solid tumor. J. Clin. Oncol 1989; 7: 75–80
   PubMed Web of Science ®Google Scholar
• Bernstein Z. P., Vaikus L., Friedman N., Goldrosen M. H., Watanabe M., Rahman E., Arbuck S. G., Sweeney J., Fesper D., Henderson E. D., Zeffren J., Dennin R. A., Levitt D., Foon A. Interleukin-2 lymphokine activated killer cells therapy of non Hodgkin's lymphoma and Hodgkin's disease. J. Immunother 1991; 10: 141–146
   PubMed Web of Science ®Google Scholar
• Weber J. S., Yang J. C., Topalian S. L., Schwarzentruber D. J., White D. E., Rosenberg S. A. The use of interleukin-2 and lymphokine activated killer cells for treatment of patients with non Hodgkin's lymphoma. J. Clin. Oncol 1992; 10: 33–40
   PubMed Web of Science ®Google Scholar
• Lim S. H., Worman C. P., Callaghan T., Jewell A., Smith M. P., Goldstone A. H. Continuous intravenous infusion of high-dose recombinant interleukin-2 for advanced lymphomas. A phase II study. Leukemia Research 1991; 15(6)435–440
   PubMed Web of Science ®Google Scholar
• Singer C. R. J., Tansey P. J., Burnett A. K. T lymphocyte reconstitution following autologous bone marrow transplantation. Clin. Exp. Immunol 1983; 51: 455–460
   PubMed Web of Science ®Google Scholar
• Charmot D., Ragueneau M., Olive D., Maraninchi D., Mawas C. Generation of CD8 cytolytic T cells early after autologous or allogeneic bone marrow transplantation. Bone Marrow Transplantation 1987; 2: 183–194
   PubMed Web of Science ®Google Scholar
• Reittie J. E., Gottlieb D., Heslop H. E., Leger O., Drexler H. G., Hazlehurst G., Hoffbrand A. V., Prentice H. G., Brenner M. K. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351–1358
   PubMed Web of Science ®Google Scholar
• Higuchi C.M., Thompson J.A., Cox T., Lindgren C.G., Buckner C. D., Fefer A. Lymphokin-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 1989; 49: 5509–5513
   PubMed Web of Science ®Google Scholar
• Hercend T., Takvorian T., Nowill A., Tantravahi R., Moingeon P., Anderson K. C., Murray C., Bohuon C., Ythier A., Ritz J. Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 1986; 67: 722–728
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Lefever A. V., Shih C. Y. Analysis of effector cells in the graft versus leukemia reaction and their relation to graft versus host disease. T-cell depletion in allogeneic bone marrow transplantation Proceedings of the Serono symposia. Ares-Serono Symposia, Rome, Italy M. F. Martelli, F. Grignani, Y. Reisner. 1988, p73
   Google Scholar
• Welte K., Ciobanu N., Moore M. A. S., Gulati S., O'Reilly R. J., Mertelsmann R. Defective interleukin-2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin-2. Blood 1984; 64: 380–385
   PubMed Web of Science ®Google Scholar
• Blaise D., Olive D., Stoppa A. M., Pourreau C., Lopez M., Attal M., Jasmin C., Monges G., Mawas C., Mannoni P., Palmer P., Francks C., Philip T., Maraninchi D. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092–1097
   PubMed Web of Science ®Google Scholar
• Blaise D., Viens P., Olive D., Stoppa A. M., Gabert J., Pourreau C., Attal M., Gaspard M. H., Mannoni P., Jasmin C., Palmer P., Francks C., Michel G., Mawas C., Baume D., Philip T., Maraninchi D. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. Eur. Cytokine. Net 1991; 2: 121–129
   PubMedGoogle Scholar
• Gottlieb D. J., Brenner M. K., Heslop H. E., Bianchi A. C. M., Bello-Fernandez C., Mehta A. B., Newland A. C., Galazka A. R., Scott E. M., Hoffbrand A. V., Prentice H. G. A phase I clinical trial of recombinant interleukin-2 following high-dose chemoradiotherapy for hematological malignancy: applicability to the elimination of minimal residual disease. Br. J. Cancer 1989; 60: 610–615
   PubMed Web of Science ®Google Scholar
• Soiffer R. J., Murray C., Cochran K., Cameron C., Wang E., Schow P. W., Daley J. F., Ritz J. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplantation. Blood 1992; 79: 517–526
   PubMed Web of Science ®Google Scholar
• Philip T., Chauvin F., Armitage J., Bron D., Hagenbeek A., Biron P., Spitzer G., Velasquez W., Weisenburger D. D., Fernandez-Ranada J., Somers R., Rizzoli V., Harousseau J. L., Sotto J. J., Cahn J. Y., Guilhot F., Biggs J., Sonneveld P., Misset J. L., Manna A., Jagannath S., Guglielmi C., Chevreau C., Delmer A., Santini G., Coiffier B. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77: 1587–1592
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Non parametric estimation from incomplete observations. J. Am. Statis. Assoc 1958; 53: 157–181
   Web of Science ®Google Scholar
• Manzel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep 1966; 50: 163–168
   PubMedGoogle Scholar
• Blaise D., Stoppa A. M., Viens P., Sainty D., Fossat C., Miquel M., Olive D., Bouabdallah R., Gabert J., Baume D., Maraninchi D. Intensive immunotherapy with recombinant interleukin-2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections. Bone marrow Transplantation 1992; 10: 193–195
   PubMed Web of Science ®Google Scholar
• Higushi C. M., Thompson J. A., Petersen F. B., Buckner C. D., Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561–2563
   PubMed Web of Science ®Google Scholar
• Weisdorf D. J., Anderson P. M., Blazar B. R., Uckun F. M., Kersey J. H., Ramsay N. K. Interleukin-2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia. A phase I study. Transplantation 1993; 55: 61–66
   PubMed Web of Science ®Google Scholar
• Gibbon J. G., Linch D. C., Singer C. R., McMiller A. K., Jarrett M., Goldstone A. H. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340–344
   PubMed Web of Science ®Google Scholar
• Rapoport A. P., Rowe J. M., Kouides P. A., Duerst R. A., Abboud C. N., Liesveld J. L., Packman C. H., Eberly S., Sherman M., Tanner M. A., Constine L. S., Dipersio J. F. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J. Clin. Oncol 1993; 11: 2351–2361
   PubMed Web of Science ®Google Scholar
• Fefer A., Benyunes M. C., Massumoto C., Higuchi C., York A., Buckner C. D., Thompson J. A. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Sem. Oncol 1993; 6: 41–45, (Suppl 9)
   Google Scholar